Evaluation of the utility of C. elegans-cancer screening test (N-NOSE) for patients with gastrointestinal cancer

Evaluation of the utility of C. elegans-cancer screening test (N-NOSE) for patients with gastrointestinal cancer - Evaluation of the utility of C. elegans-cancer screening test (N-NOSE) for patients with gastrointestinal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042740

Enrollment

Registered

2020-12-13

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Histologically diagnosed gastric or esophageal cancer (2)20 years and over at the timing of registration (3)ECOG Performance status(PS) of 0 or 1 (4)Organ function is preserved (5)Curative resection is planned (6)Written informed consent is obtained

Exclusion criteria

Exclusion criteria: (1)Synchronous or metachronous (within five years) multiple cancers, except for intraepithelial or intramucosal carcinoma cured by local therapy (2)Active systemic infectious disease (3)Unable to join due to his/her mental status or mental disorders (4)Pregnancy, lactation, or intention to become pregnant during this study (5)Whom judged by the investigator, sub-investigator, or attending physician to be ineligible for enrollment in the study

Design outcomes

Primary

Measure	Time frame
The change of the chemotaxis index before and after treatment	—

Secondary

Measure	Time frame
The association between the change of chemotaxis-index and the response for treatments	—

Countries

Japan

Contacts

Public ContactSayuri Iitaka

Graduate School of Medicine, The University of Tokyo Department of Gastrointestinal Surgery

iitaka-spr@umin.ac.jp03-3815-5411

Outcome results